 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 218
A lot of the buzz at the 2024 ASH conference we attended recently was about Revlimid (generic name: lenalidomide). Everyone was talking about it — and not just for Multiple Myeloma or MDS (myelodisplastic syndrome), for which it has FDA approval. Revlimid is now being studied for relapsed CLL patients and there were two major presentations at ASH on the subject, one from M. D. Anderson and the other from Roswell Park.
I have to admit to some misgivings about this drug but here is the latest information on Revlimid and its potential value as a CLL drug – you can make up your own mind about it after reading our review, Revlimid to the Rescue?. Revlimid has pretty significant list of adverse effects and hematological toxicity. But it shows some promise in treating patients with poor prognosis and for that reason we are likely to hear more about it in the months to come.
Celgene (the company that owns Revlimid) has launched an ambitious Phase III clinical trial of Revlimid in previously treated CLL patients. See listing on Clinicaltrials.gov. They are looking to recruit a large number of people (as many as 310 patients), and this is no easy task. I expect the company will be doing all it can to get the word out to local oncologists to refer their patients to this clinical trial. If you are considering participation in this (or other) Revlimid trials, I would advise you to read our review of the Phase II trial results before you sign on the dotted line.
If you decide Revlimid is right for you and sign up, do share any information you get with us! As always, we promise total confidentiality – your name will never be disclosed. Your feedback is very important in helping us stay relevant to the needs of our patient community.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
